Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

BTIG cuts Talis Biomedical to sell; PT $1

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “sell” from “neutral” with a price target of $1, citing a delay in the beta-phase rollout of the Talis One COVID-19 diagnostic, which was planned for the first quarter...

March 18, 2022

Markets

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform” from “outperform” and trimmed its price target to $4 (Canadian) from $5, citing a slower than expected enrollment in Cardiol’s LANCER clinical...

March 16, 2022

Markets

Maxim starts Unicycive Therapeutics at buy; PT $3

Maxim Group initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a “buy” rating and price target of $3. The stock closed at $1.07 on March 15. Unicycive is aiming to bring two key assets through clinical...

March 16, 2022

Markets

SVB Leerink starts Pardes Biosciences at OP; PT $18

SVB Leerink launched coverage of Pardes Biosciences (NASDAQ:PRDS) with an “outperform” rating and $18 price target. The stock closed at $5.54 on March 14. Pardes is a clinical-stage biopharmaceutical company created to...

March 15, 2022

Markets

HCW starts Esperion at buy; PT $22

H.C. Wainwright initiated coverage of Esperion Therapeutics (NASDAQ:ESPR) with a “buy” rating and price target of $22. The stock closed at $4.57 on March 9. Esperion is a commercial-stage company focused on development...

March 10, 2022

Markets

Stifel ups IDEAYA Biosciences to buy; PT cut to $20

Stifel upgraded IDEAYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” but cut its price target to $20 from $27, saying the risk/reward around the company’s IDE397 drug candidate is favorable with the stock in the mid-to...

March 10, 2022

Markets

WB starts Brickell Biotech at OP; fair value estimate $2

William Blair initiated coverage of Brickell Biotech (NASDAQ:BBI) with an “outperform” rating and fair value estimate of $2. The stock closed at 21 cents on March 7. Brickell is a biopharmaceutical company focused on...

March 8, 2022

Markets

SVB Leerink cuts Gemini Therapeutics to MP; PT to $2

SVB Leerink downgraded Gemini Therapeutics (NASDAQ:GMTX) to “market perform” from “outperform” and slashed its price target to $2 from $10, citing an unexpected leadership transition and corporate restructuring. The...

March 3, 2022

Markets

Stifel resumes coverage of Rhythm Pharma at buy; PT $23

Stifel resumed coverage of Rhythm Pharmaceuticals (NASDAQ:RYTM) with a “buy” rating and $23 price target. The stock closed at $8.49 on March 1. Rhythm is a commercial biopharmaceutical company developing therapeutics...

March 2, 2022

Markets

Brookline ups CTI Biopharma PT to $12 from $7.20

Brookline Capital Markets raised its price target for CTI Biopharma (NASDAQ:CTIC) to $12 from $7.20 after the FDA approved Vonjo in myelofibrosis. The stock closed at $3.10, up $1.20, on volume of 108 million shares on...

March 1, 2022

Markets

WB starts Arcellx at OP; fair value estimate $40

William Blair initiated coverage of Arcellx (NASDAQ:ACLX) with an “outperform” rating and fair value estimate of $40. The stock closed at $16.94 on Feb. 28. Arcellx’s next-generation cell therapy platform is founded on...

March 1, 2022

Markets

HCW cuts Celyad Oncology to neutral; removes PT

H.C. Wainwright downgraded Celyad Oncology (NASDAQ:CYAD) to “neutral” from “buy” and removed its price target after the company paused dosing and enrollment in its Phase 1b KEYNOTE-B79 study. Shares of Celyad were...

February 28, 2022

Markets

Cantor starts Hepion Pharma at OW; PT $3.50

Cantor Fitzgerald launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with an “overweight” rating and $3.50 price target. The stock closed at $1.03 on Feb. 25. Hepion’s lead asset, Rencofilstat (CRV431)...

February 28, 2022

Markets

Cantor starts Journey Medical at OW; PT $9

Cantor Fitzgerald initiated coverage of Journey Medical (NASDAQ:DERM) with an “overweight” rating and a 12-month price target of $9. The stock finished at $5.07 on Feb. 24. Journey is building a portfolio of commercial...

February 25, 2022

Markets

Stifel cuts MacroGenics PT to $26 from $44; maintains buy rating

Stifel reduced its price target for MacroGenics (NASDAQ:MGNX) to $26 from $44 but maintained its “buy” rating, citing multiple pipeline updates in the company’s fourth quarter report. The stock closed at $10.49 on Feb...

February 25, 2022

Markets

Maxim starts NexGel at buy; PT $6

Maxim Group initiated coverage of NexGel (NASDAQ:NXGL) with a “buy” rating and a price target of $6. The stock closed at $1.81 on Feb. 24. NexGel manufactures, develops, and commercializes topical hydrogel-based...

February 25, 2022

Markets

BTIG starts Oncternal at buy; PT $5

BTIG launched coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and $5 price target. The stock closed at $1.73 on Feb. 23. Oncternal is a clinical-stage biotechnology company focused on a diverse...

February 24, 2022

Markets

BTIG cuts iCAD PT to $12 from $25; maintains buy rating

BTIG slashed its price target for iCAD (NASDAQ:ICAD) to $12 from $25 but maintained its “buy” rating, ahead of the company’s fourth quarter earnings report next week. The stock closed at $4.97 on Feb. 23. In a...

February 23, 2022

Markets

Cantor starts Affimed at OW; PT $12

Cantor Fitzgerald initiated coverage of Affimed N.V. (NASDAQ:AFMD) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.23 on Feb. 22. Affimed, which is one of Cantor’s top picks for...

February 23, 2022

Markets

BTIG cuts Zosano to neutral from buy; removes PT

BTIG downgraded Zosano Pharma (NASDAQ:ZSAN) to “neutral” from “buy” and removed its price target after the FDA refused to accept the company’s NDA resubmission for M207 to treat acute migraine. Shares of Zosano, which...

February 23, 2022

Markets

Raymond James starts Medexus at OP; PT $5.50 (Canadian)

Raymond James initiated coverage of Medexus Pharmaceuticals (TSX:MDP) with an “outperform” rating and price target of $5.50 (Canadian). The stock closed at $3.32 on Feb. 18. Medexus is a fully integrated, specialty...

February 22, 2022

Markets

Cantor starts vTv at OW; PT $5

Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...

February 18, 2022

Subscribe